☰
Skip to content
Home
Studies
BioFINDER One
BioFINDER Two
BioFINDER Sleep
BioFINDER Preclinical AD
BioFINDER Primare Care
BioFINDER Memory Clinic
Study Group
Publications
News
Deltagare / Participants
Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?
2016
Brain. 2016 Jul 6. pii: aww169.
Palmqvist S
1
,
Mattsson N
1
,
Hansson O
2
.
2024
Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study
2024
Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity
2024
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
2024
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
2024
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
2024
Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease
2024
Revised criteria for the diagnosis and staging of Alzheimer’s disease
2024
Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
2024
Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals
2024
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
2024
In vivo detection of Alzheimer’s and Lewy body disease concurrence: Clinical implications and future perspectives
2024
Structural and functional connectivity associations with anterior cingulate sulcal variability
2024
Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study
2024
MRI-Derived AD Signature of Cortical Thinning and Plasma P-Tau217 for Predicting Alzheimer Dementia Among Community-Dwelling Older Adults
2024
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology